ClinicalTrials.gg
CompletedNCT00989235Updated Jun 21, 2011Results posted

Substudy - Low Dose of Abatacept in Subjects With Rheumatoid Arthritis

A Phase 3 interventional study of Abatacept and Abatacept in Rheumatoid Arthritis, sponsored by Bristol-Myers Squibb. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-06-21.

Sponsored by Bristol-Myers Squibb · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
108
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 63 studies testing abatacept in Arthritis, Rheumatoid — 3 open to participants now, 4 under way, 3 of them phase 3. Abatacept · Arthritis, Rheumatoid.

Enrollment
35th of 63
108 · median 119
Started
2007
with 5 others
Phase 3
26 of 63
2 open now
Registered
23rd of 63
by date
Lead sponsor
33 of 63
Bristol-Myers Squibb

Among the 63 studies testing abatacept in Arthritis, Rheumatoid, this one is the 35th largest by enrollment, is one of 6 that started in 2007, is one of 26 in phase 3, and was the 23rd registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

3 of the 63 studies testing abatacept in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About abatacept

Abatacept: first FDA approval 2005 (ORENCIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 63 studies testing abatacept in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

The purpose of this exploratory sub-study was to evaluate from a clinical perspective the impact on disease activity of lowering the dose of abatacept from 10 mg/kg to 5 mg/kg in subjects who had achieved remission (Disease Activity Score 28 [DAS 28]-erythrocyte sedimentation rate [ESR] \< 2.6) at Day 701 of study IM101023.

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • NOS
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who have completed the main study, are willing to participate and have a DAS 28 ESR score of \< 2.6 on Day 701 of the main study

Exclusion criteria

Exclusion Criteria:

  • None
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
108 participants (actual)

Study arms

  • Active comparator
    Abatacept (10 mg/Kg)

    Drug: Abatacept

  • Active comparator
    Abatacept (5 mg/Kg)

    Drug: Abatacept

Interventions

  • IV solution, IV, 10 mg/Kg, Once monthly, 1 year

    Also known as: BMS-188667

  • IV solution, IV, 5 mg/Kg, Once monthly, 1 year

    Also known as: BMS-188667

06

What researchers measure

Primary outcomes

  1. Time to Disease Relapse Through Month 12 (Kaplan-Meier Cumulative Percentage of Events of Disease Relapse)

    An event of disease relapse was defined as additional Disease-modifying antirheumatic drug (DMARD) therapy given, or 2 or more courses of high steroids given, or return to abatacept 10 mg/kg (rescue medication given), or DAS28 C-reactive protein (CRP) score \>=3.2 at 2 consecutive visits. Time to disease relapse was evaluated using life tables (Kaplan-Meier Cumulative Percentage of Events of Disease Relapse).

    Time frame: Months 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12

Secondary outcomes

  1. Number of Participants Experiencing Disease Relapse

    Disease relapse is defined as additional DMARD therapy given, or 2 or more courses of high steroids given, or return to abatacept 10 mg/kg (rescue medication given), or DAS28 CRP score \>= 3.2 at 2 consecutive visits.

    Time frame: After 12 Months of treatment

  2. Mean Time-Matched Baseline DAS28 CRP Scores

    Mean baseline DAS28 CRP values for the cohort of participants with serum samples available at that timepoint. DAS 28 is a continuous variable which is a composite of 4 variables: number of tender joints out of 28, number of swollen joints out of 28 joints, CRP in mg/L and subject assessment of disease activity measure on a visual analogue scale (VAS) of 100 mm. The DAS28 provides a score on a scale from 0 to 10 indicating the current activity of the rheumatoid arthritis (\>5.1=high disease activity; \<3.2=low disease activity; \<2.6=remission).

    Time frame: Baseline

  3. Adjusted Mean Change From Baseline in DAS28 CRP During Double-Blind Treatment

    Mean baseline DAS28 CRP values for the cohort of participants with serum samples available at that timepoint. DAS 28 is a continuous variable which is a composite of 4 variables: number of tender joints out of 28, number of swollen joints out of 28 joints, CRP in mg/L and subject assessment of disease activity measure on a VAS of 100 mm. The DAS28 provides a score on a scale from 0 to 10 indicating the current activity of the rheumatoid arthritis (\>5.1=high disease activity; \<3.2=low disease activity; \<2.6=remission).

    Time frame: Baseline, Days 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, 337, 365

  4. Percentage of Participants With 2 Consecutive DAS 28 CRP Scores ≥ 3.2 (Loss of Low Disease Activity Status)

    DAS 28 is a continuous variable which is a composite of 4 variables: number of tender joints out of 28, number of swollen joints out of 28 joints, CRP in mg/L and subject assessment of disease activity measure on a VAS of 100 mm. The DAS28 provides a score on a scale from 0 to 10 indicating the current activity of the rheumatoid arthritis (\>5.1=high disease activity; \<3.2=low disease activity; \<2.6=remission).

    Time frame: After 12 months of treatment

  5. Percentage of Participants Given Additional DMARD Therapy During Double-Blind Treatment

    Additional DMARD therapy is defined as a re-introduction of methotrexate (MTX), an increase of at least 2.5 mg of MTX, or the addition of at least 1 DMARD.

    Time frame: After 12 months of treatment

  6. Percentage of Participants Who at Any Time During Double-Blind Treatment Were Given 2 or More Courses of High-Dose Steroids

    A course of high dose steroids is defined as a course of intramuscular, intravenous, or high dose oral corticosteroids (use of \> 10 mg/day equivalent of prednisone for a minimum of 3 consecutive days or for those subjects who had continued use for long durations of time, each course was determined by 28 day intervals).

    Time frame: After 12 months of treatment

  7. Percentage of Participants Given Rescue Medication Therapy During Double-Blind Treatment

    All subjects in the sub-study randomized to receive double-blind abatacept 5 mg/kg or 10 mg/kg. Subjects rescued to open-label treatment received abatacept 10 mg/kg.

    Time frame: After 12 months of treatment

  8. Percentage of Participants Who Modified Therapy During Double-Blind Treatment

    Modified therapy=additional DMARD therapy, 2 or more courses of high dose steroids or rescue medication. Additional DMARD therapy=re-introduction of methotrexate (MTX), an increase of at least 2.5 mg of MTX, or the addition of at least 1 DMARD. A course of high dose steroids=a course of intramuscular, intravenous, or high dose oral corticosteroids (use of \> 10 mg/day equivalent of prednisone for a minimum of 3 consecutive days or for those subjects who had continued use for long durations of time, each course was determined by 28 day intervals). Rescue medication=abatacept 10 mg/kg.

    Time frame: After 12 months of treatment

  9. Percentage of Participants Who Lost Remission Status

    Loss of remission is defined as DAS 28 CRP \>=2.6.

    Time frame: After 12 months of treatment

  10. Steady-state Trough Serum Concentration (Cmin) of Abatacept During Double-Blind Treatment

    Time frame: Day 701 of the main study; sub-study Days 1, 85, 169, 253

  11. Percentage of Participants With Adverse Events (AEs), Serious AEs (SAEs), Deaths, and Discontinuations During Double-Blind Treatment

    AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. Related AE/SAE=Certain, Probable, Possible, or Missing. SAE=any untoward medical occurrence that results in death, is life-threatening, requires or prolongs inpatient hospitalization (including elective surgery), results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event.

    Time frame: From start of substudy up to 56 days post last dose in the double-blind period or start of the open-label rescue period, whichever occurred first until end of study (study duration was 115 weeks)

  12. Percentage of Participants With Infection and Infestation AEs Reported During Double-Blind Treatment

    AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. Infection and Infestation AEs = any AE within the System Organ Class Infection and Infestation.

    Time frame: From start of substudy up to 56 days post last dose in the double-blind period or start of the open-label rescue period, whichever occurred first until end of study (study duration was 115 weeks)

  13. Percentage of Participants With Malignant Neoplasms Reported During Double-Blind Treatment

    All neoplasms were assessed by medical review as to whether or not the event was malignant.

    Time frame: From start of substudy up to 56 days post last dose in the double-blind period or start of the open-label rescue period, whichever occurred first until end of study (study duration was 115 weeks)

  14. Percentage of Participants With Prespecified Acute Infusional Adverse Events (AIAEs) During Double-Blind Treatment, by Intensity

    AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. Acute Infusional AE= a subset of the peri-infusional AEs with onset during the first hour after the start of the study drug infusion. A total of 105 infusional events were prespecified in the protocol.

    Time frame: From start of substudy up to 56 days post last dose in the double-blind period or start of the open-label rescue period, whichever occurred first until end of study (study duration was 115 weeks)

  15. Percentage of Participants With Prespecified Peri-Infusional Adverse Events (PAIAEs) During Double-Blind Treatment, by Intensity

    AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. Peri-infusional AE=a pre-specified infusional AE occuring during the first 24 hours after the start of study drug infusion.A total of 105 infusional events were prespecified in the protocol. GDASC=General Disorders and Administration Site Conditions, RTMD=Respiratory, Thoracic and Mediastinal Disorders.

    Time frame: From start of substudy up to 56 days post last dose in the double-blind period or start of the open-label rescue period, whichever occurred first until end of study (study duration was 115 weeks)

  16. Percentage of Participants With Pre-specified Autoimmune Disorders (ADs) Reported During Double-Blind Treatment, by Intensity

    A total of 127 autoimmune disorders were prespecified in the protocol. MCTD=Musculoskeletal and Connective Tissue Disorders

    Time frame: From start of substudy up to 56 days post last dose in the double-blind period or start of the open-label rescue period, whichever occurred first until end of study (study duration was 115 weeks)

  17. Percentage of Participants With Laboratory Values Meeting the Marked Abnormality Criteria During Double-Blind Treatment

    Not evaluated: high hemoglobin,high hematocrit,high erythrocytes,high neutrophils+bands(N+B),low monocytes,low basophils,low eosinophils,low alkaline phosphatase(ALP),low aspartate aminotransferase(AST),low alanine aminotransferase(ALT),low G-Glutamyl transferase(GGT),low total bilirubin,low blood urea nitrogen,low creatinine,high albumin,low uric acid,low urine protein,low urine glucose,low urine blood,low urine leukocyte esterase,low urine white blood cells,low red blood cells.Pre Rx=pretreatment,(\*)Lymphocytes(c/uL):Low\<.750x10\^3,High\>7.50x10\^3.(\*)Eosinophils:\>.750x10\^3 c/uL.

    Time frame: From start of substudy up to 56 days post last dose in the double-blind period or start of the open-label rescue period, whichever occurred first until end of study (study duration was 115 weeks)

  18. Clinically Significant Changes in Vital Signs and Physical Findings

    Clinical significance was determined by investigator. Parameters include blood pressure, heart rate, respiration rate, and temperature.

    Time frame: From start of substudy up to 56 days post last dose in the double-blind period or start of the open-label rescue period, whichever occurred first until end of study (study duration was 115 weeks)

  19. Participants With Positive Antibody Responses to Abatacept (Electrochemiluminescence [ECL] Method) During Double-Blind Treatment

    A positive antibody response to Abatacept (measured by the ECL assay) is further classified as a positive response for either Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) and Possibly immunoglobulin (Ig)' or 'Ig and/or Junction Region'

    Time frame: After 12 months of treatment

07

Results

Posted Jun 3, 2011

Participant flow

IM101023 (NCT00122382) was a 2-year study completing on Day 729, in which subjects were randomized to receive abatacept or placebo in combination with methotrexate (MTX) for the 1st year of the study and were then switched to open-label abatacept+MTX in the 2nd year. All subjects had received abatacept for a least 1 year prior start of sub-study.

Participant flow — Overall Study
MilestoneAbatacept (10 mg/kg)Abatacept (5 mg/kg)
Started5850
Number rescued to open-label treatment44
Number completing double-blind treatment5141
Completed5544
Not completed36
Withdrew: Death01
Withdrew: Adverse event01
Withdrew: Lack of efficacy10
Withdrew: Withdrawal of consent11
Withdrew: Desire to become pregnant10
Withdrew: Randomized by mistake02
Withdrew: Lost to follow-up01

Outcome measures

SecondaryNumber of Participants Experiencing Disease Relapse

Disease relapse is defined as additional DMARD therapy given, or 2 or more courses of high steroids given, or return to abatacept 10 mg/kg (rescue medication given), or DAS28 CRP score \>= 3.2 at 2 consecutive visits.

Time frame:
After 12 Months of treatment
Reported as:
Number · Participants
Number of Participants Experiencing Disease Relapse
ParticipantsAbatacept (10 mg/kg)Abatacept (5 mg/kg)
Number of Participants Experiencing Disease Relapse1817
SecondaryMean Time-Matched Baseline DAS28 CRP Scores

Mean baseline DAS28 CRP values for the cohort of participants with serum samples available at that timepoint. DAS 28 is a continuous variable which is a composite of 4 variables: number of tender joints out of 28, number of swollen joints out of 28 joints, CRP in mg/L and subject assessment of disease activity measure on a visual analogue scale (VAS) of 100 mm. The DAS28 provides a score on a scale from 0 to 10 indicating the current activity of the rheumatoid arthritis (\>5.1=high disease activity; \<3.2=low disease activity; \<2.6=remission).

Time frame:
Baseline
Reported as:
Mean · units on a scale
Mean Time-Matched Baseline DAS28 CRP Scores
units on a scaleAbatacept (10 mg/kg)Abatacept (5 mg/kg)
Day 29 Cohort (n=45, 40)2.09 ± 0.612.05 ± 0.60
Day 57 Cohort (n=47, 37)2.06 ± 0.592.06 ± 0.62
Day 85 Cohort (n=46, 42)2.10 ± 0.602.09 ± 0.60
Day 113 Cohort (n=49, 39)2.06 ± 0.612.09 ± 0.62
Day 141 Cohort (n=47, 40)2.09 ± 0.592.10 ± 0.62
Day 169 Cohort (n=46, 36)2.10 ± 0.592.04 ± 0.61
Day 197 Cohort (n=44, 38)2.08 ± 0.602.06 ± 0.61
Day 225 Cohort (n=44, 38)2.09 ± 0.602.08 ± 0.63
Day 253 Cohort (n=46, 37)2.07 ± 0.602.04 ± 0.61
Day 281 Cohort (n=45, 38)2.07 ± 0.612.06 ± 0.61
Day 309 Cohort (n=45, 37)2.10 ± 0.582.08 ± 0.61
Day 337 Cohort (n=44, 36)2.09 ± 0.602.08 ± 0.62
Day 365 Cohort (n=41, 35)2.02 ± 0.602.08 ± 0.60
SecondaryAdjusted Mean Change From Baseline in DAS28 CRP During Double-Blind Treatment

Mean baseline DAS28 CRP values for the cohort of participants with serum samples available at that timepoint. DAS 28 is a continuous variable which is a composite of 4 variables: number of tender joints out of 28, number of swollen joints out of 28 joints, CRP in mg/L and subject assessment of disease activity measure on a VAS of 100 mm. The DAS28 provides a score on a scale from 0 to 10 indicating the current activity of the rheumatoid arthritis (\>5.1=high disease activity; \<3.2=low disease activity; \<2.6=remission).

Time frame:
Baseline, Days 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, 337, 365
Reported as:
Mean · units on a scale
Adjusted Mean Change From Baseline in DAS28 CRP During Double-Blind Treatment
units on a scaleAbatacept (10 mg/kg)Abatacept (5 mg/kg)
Day 29 (n=45, 40)0.24 ± 0.100.06 ± 0.10
Day 57 (n=47, 37)0.05 ± 0.090.14 ± 0.10
Day 85 (n=46, 42)0.13 ± 0.100.21 ± 0.10
Day 113 (n=49, 39)0.02 ± 0.090.25 ± 0.10
Day 141 (n=47, 40)0.32 ± 0.100.29 ± 0.11
Day 169 (n=46, 36)0.13 ± 0.090.26 ± 0.11
Day 197 (n=44, 38)0.09 ± 0.090.22 ± 0.09
Day 225 (n=44, 38)0.25 ± 0.100.29 ± 0.10
Day 253 (n=46, 37)0.23 ± 0.090.14 ± 0.10
Day 281 (n=45, 38)0.18 ± 0.080.05 ± 0.09
Day 309 (n=45, 37)0.07 ± 0.080.09 ± 0.09
Day 337 (n=44, 36)0.26 ± 0.110.29 ± 0.13
Day 365 (n=41, 35)0.39 ± 0.110.16 ± 0.12
Statistical analysis
  • Abatacept (10 mg/kg) vs Abatacept (5 mg/kg) · ANCOVA · Adjusted difference: 0.18 · 95% CI -0.11 to 0.46Change from Baseline = Post-baseline - Baseline value.
  • Abatacept (10 mg/kg) vs Abatacept (5 mg/kg) · ANCOVA · Adjusted difference: -0.09 · 95% CI -0.34 to 0.17Change from Baseline = Post-baseline - Baseline value.
  • Abatacept (10 mg/kg) vs Abatacept (5 mg/kg) · ANCOVA · Adjusted difference: -0.08 · 95% CI -0.37 to 0.20Change from Baseline = Post-baseline - Baseline value.
  • Abatacept (10 mg/kg) vs Abatacept (5 mg/kg) · ANCOVA · Adjusted difference: -0.23 · 95% CI -0.50 to 0.04Change from Baseline = Post-baseline - Baseline value.
  • Abatacept (10 mg/kg) vs Abatacept (5 mg/kg) · ANCOVA · Adjusted difference: 0.03 · 95% CI -0.26 to 0.32Change from Baseline = Post-baseline - Baseline value.
  • Abatacept (10 mg/kg) vs Abatacept (5 mg/kg) · ANCOVA · Adjusted difference: -0.13 · 95% CI -0.41 to 0.15Change from Baseline = Post-baseline - Baseline value.
  • Abatacept (10 mg/kg) vs Abatacept (5 mg/kg) · ANCOVA · Adjusted difference: -0.12 · 95% CI -0.38 to 0.13Change from Baseline = Post-baseline - Baseline value.
  • Abatacept (10 mg/kg) vs Abatacept (5 mg/kg) · ANCOVA · Adjusted difference: -0.04 · 95% CI -0.32 to 0.25Change from Baseline = Post-baseline - Baseline value.
  • Abatacept (10 mg/kg) vs Abatacept (5 mg/kg) · ANCOVA · Adjusted difference: 0.08 · 95% CI -0.19 to 0.36Change from Baseline = Post-baseline - Baseline value.
  • Abatacept (10 mg/kg) vs Abatacept (5 mg/kg) · ANCOVA · Adjusted difference: 0.13 · 95% CI -0.12 to 0.38Change from Baseline = Post-baseline - Baseline value.
  • Abatacept (10 mg/kg) vs Abatacept (5 mg/kg) · ANCOVA · Adjusted difference: -0.03 · 95% CI -0.27 to 0.22Change from Baseline = Post-baseline - Baseline value.
  • Abatacept (10 mg/kg) vs Abatacept (5 mg/kg) · ANCOVA · Adjusted difference: -0.03 · 95% CI -0.37 to 0.31Change from Baseline = Post-baseline - Baseline value.
  • Abatacept (10 mg/kg) vs Abatacept (5 mg/kg) · ANCOVA · Adjusted difference: 0.23 · 95% CI -0.09 to 0.55Change from Baseline = Post-baseline - Baseline value.
SecondaryPercentage of Participants With 2 Consecutive DAS 28 CRP Scores ≥ 3.2 (Loss of Low Disease Activity Status)

DAS 28 is a continuous variable which is a composite of 4 variables: number of tender joints out of 28, number of swollen joints out of 28 joints, CRP in mg/L and subject assessment of disease activity measure on a VAS of 100 mm. The DAS28 provides a score on a scale from 0 to 10 indicating the current activity of the rheumatoid arthritis (\>5.1=high disease activity; \<3.2=low disease activity; \<2.6=remission).

Time frame:
After 12 months of treatment
Reported as:
Number · percentage of participants
Percentage of Participants With 2 Consecutive DAS 28 CRP Scores ≥ 3.2 (Loss of Low Disease Activity Status)
percentage of participantsAbatacept (10 mg/kg)Abatacept (5 mg/kg)
Percentage of Participants With 2 Consecutive DAS 28 CRP Scores ≥ 3.2 (Loss of Low Disease Activity Status)22.4 (11.7 to 33.1)22.0 (10.5 to 33.5)
Statistical analysis
  • Abatacept (10 mg/kg) vs Abatacept (5 mg/kg) · normal approximation · Estimate of difference: 0.4 · 95% CI -17.2 to 18.0For 95% CI: normal approximation with continuity correction.
SecondaryPercentage of Participants Given Additional DMARD Therapy During Double-Blind Treatment

Additional DMARD therapy is defined as a re-introduction of methotrexate (MTX), an increase of at least 2.5 mg of MTX, or the addition of at least 1 DMARD.

Time frame:
After 12 months of treatment
Reported as:
Number · percentage of participants
Percentage of Participants Given Additional DMARD Therapy During Double-Blind Treatment
percentage of participantsAbatacept (10 mg/kg)Abatacept (5 mg/kg)
Percentage of Participants Given Additional DMARD Therapy During Double-Blind Treatment3.4 (-1.2 to 8.1)12.0 (3.0 to 21.0)
Statistical analysis
  • Abatacept (10 mg/kg) vs Abatacept (5 mg/kg) · normal approximation · Estimate of difference: -8.6 · 95% CI -20.3 to 3.2For 95% CI: normal approximation with continuity correction.
SecondaryPercentage of Participants Who at Any Time During Double-Blind Treatment Were Given 2 or More Courses of High-Dose Steroids

A course of high dose steroids is defined as a course of intramuscular, intravenous, or high dose oral corticosteroids (use of \> 10 mg/day equivalent of prednisone for a minimum of 3 consecutive days or for those subjects who had continued use for long durations of time, each course was determined by 28 day intervals).

Time frame:
After 12 months of treatment
Reported as:
Number · percentage of participants
Percentage of Participants Who at Any Time During Double-Blind Treatment Were Given 2 or More Courses of High-Dose Steroids
percentage of participantsAbatacept (10 mg/kg)Abatacept (5 mg/kg)
Percentage of Participants Who at Any Time During Double-Blind Treatment Were Given 2 or More Courses of High-Dose Steroids0 (0 to 0)0 (0 to 0)
PrimaryTime to Disease Relapse Through Month 12 (Kaplan-Meier Cumulative Percentage of Events of Disease Relapse)

An event of disease relapse was defined as additional Disease-modifying antirheumatic drug (DMARD) therapy given, or 2 or more courses of high steroids given, or return to abatacept 10 mg/kg (rescue medication given), or DAS28 C-reactive protein (CRP) score \>=3.2 at 2 consecutive visits. Time to disease relapse was evaluated using life tables (Kaplan-Meier Cumulative Percentage of Events of Disease Relapse).

Time frame:
Months 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
Reported as:
Number · Percentage of Events
Time to Disease Relapse Through Month 12 (Kaplan-Meier Cumulative Percentage of Events of Disease Relapse)
Percentage of EventsAbatacept (10 mg/kg)Abatacept (5 mg/kg)
Month 1 (n=55, 49)5.172.00
Month 2 (n=52, 47)8.654.00
Month 3 (n=51, 42)10.4112.35
Month 4 (n=50, 38)12.1722.78
Month 5 (n=47, 35)13.9626.96
Month 6 (n=42, 33)23.1131.13
Month 7 (n=41, 32)24.9433.22
Month 8 (n=40, 31)26.7733.22
Month 9 (n=38, 31)30.4333.22
Month 10 (n=37, 31)32.2733.22
Month 11 (n=37, 30)32.2735.37
Month 12 (n=36, 28)32.2735.37
Statistical analysis
  • Abatacept (10 mg/kg) vs Abatacept (5 mg/kg) · Cox proportional hazards model · Hazard ratio (hr): 0.870 · 95% CI 0.45 to 1.69Hazard ratio determined by a Cox proportional hazards model with treatment as the only covariate.
SecondaryPercentage of Participants Given Rescue Medication Therapy During Double-Blind Treatment

All subjects in the sub-study randomized to receive double-blind abatacept 5 mg/kg or 10 mg/kg. Subjects rescued to open-label treatment received abatacept 10 mg/kg.

Time frame:
After 12 months of treatment
Reported as:
Number · percentage of participants
Percentage of Participants Given Rescue Medication Therapy During Double-Blind Treatment
percentage of participantsAbatacept (10 mg/kg)Abatacept (5 mg/kg)
Percentage of Participants Given Rescue Medication Therapy During Double-Blind Treatment6.9 (0.4 to 13.4)8.0 (0.5 to 15.5)
Statistical analysis
  • Abatacept (10 mg/kg) vs Abatacept (5 mg/kg) · normal approximation · Estimate of difference: -1.1 · 95% CI -12.9 to 10.7For 95% CI: normal approximation with continuity correction.
SecondaryPercentage of Participants Who Modified Therapy During Double-Blind Treatment

Modified therapy=additional DMARD therapy, 2 or more courses of high dose steroids or rescue medication. Additional DMARD therapy=re-introduction of methotrexate (MTX), an increase of at least 2.5 mg of MTX, or the addition of at least 1 DMARD. A course of high dose steroids=a course of intramuscular, intravenous, or high dose oral corticosteroids (use of \> 10 mg/day equivalent of prednisone for a minimum of 3 consecutive days or for those subjects who had continued use for long durations of time, each course was determined by 28 day intervals). Rescue medication=abatacept 10 mg/kg.

Time frame:
After 12 months of treatment
Reported as:
Number · percentage of participants
Percentage of Participants Who Modified Therapy During Double-Blind Treatment
percentage of participantsAbatacept (10 mg/kg)Abatacept (5 mg/kg)
Percentage of Participants Who Modified Therapy During Double-Blind Treatment10.3 (2.5 to 18.2)18.0 (7.4 to 28.6)
Statistical analysis
  • Abatacept (10 mg/kg) vs Abatacept (5 mg/kg) · normal approximation · Estimate of difference: -7.7 · 95% CI -22.6 to 7.395% CI: normal approximation with continuity correction.
SecondaryPercentage of Participants Who Lost Remission Status

Loss of remission is defined as DAS 28 CRP \>=2.6.

Time frame:
After 12 months of treatment
Reported as:
Number · percentage of participants
Percentage of Participants Who Lost Remission Status
percentage of participantsAbatacept (10 mg/kg)Abatacept (5 mg/kg)
Percentage of Participants Who Lost Remission Status53.4 (40.6 to 66.3)64.0 (50.7 to 77.3)
Statistical analysis
  • Abatacept (10 mg/kg) vs Abatacept (5 mg/kg) · normal approximation · Estimate of difference: -10.6 · 95% CI -31.1 to 10.095% CI: normal approximation with continuity correction.
SecondarySteady-state Trough Serum Concentration (Cmin) of Abatacept During Double-Blind Treatment
Time frame:
Day 701 of the main study; sub-study Days 1, 85, 169, 253
Reported as:
Mean · ng/mL
Steady-state Trough Serum Concentration (Cmin) of Abatacept During Double-Blind Treatment
ng/mLAbatacept (10 mg/kg)Abatacept (5 mg/kg)
Main Study Day 701 (n=41, 36)22992.0 ± 9722.121713.5 ± 9520.5
Sub-Study Day 1 (n=46, 41)22213.0 ± 9275.823620.7 ± 9648.0
Sub-Study Day 85 (n=47, 43)24919.5 ± 14516.211922.1 ± 5681.8
Sub-Study Day 169 (n=48, 43)25725.7 ± 18500.59959.2 ± 5045.0
Sub-Study Day 253 (n=47, 42)28524.7 ± 19989.913516.2 ± 6564.6
SecondaryPercentage of Participants With Adverse Events (AEs), Serious AEs (SAEs), Deaths, and Discontinuations During Double-Blind Treatment

AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. Related AE/SAE=Certain, Probable, Possible, or Missing. SAE=any untoward medical occurrence that results in death, is life-threatening, requires or prolongs inpatient hospitalization (including elective surgery), results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, or is an important medical event.

Time frame:
From start of substudy up to 56 days post last dose in the double-blind period or start of the open-label rescue period, whichever occurred first until end of study (study duration was 115 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With Adverse Events (AEs), Serious AEs (SAEs), Deaths, and Discontinuations During Double-Blind Treatment
percentage of participantsAbatacept (10 mg/kg)Abatacept (5 mg/kg)
Deaths02.0
SAEs5.26.0
Related SAEs1.70
Discontinued due to SAEs02.0
AEs65.550.0
Related AEs20.710.0
Discontinued due to AEs02.0
SecondaryPercentage of Participants With Infection and Infestation AEs Reported During Double-Blind Treatment

AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. Infection and Infestation AEs = any AE within the System Organ Class Infection and Infestation.

Time frame:
From start of substudy up to 56 days post last dose in the double-blind period or start of the open-label rescue period, whichever occurred first until end of study (study duration was 115 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With Infection and Infestation AEs Reported During Double-Blind Treatment
percentage of participantsAbatacept (10 mg/kg)Abatacept (5 mg/kg)
Total Participants with Infection and Infestation37.926.0
Upper Respiratory Tract Infection5.212.0
Nasopharyngitis5.26.0
Influenza5.24.0
Bronchitis5.22.0
Urinary Tract Infection3.44.0
Onychomycosis3.42.0
Pharyngitis3.42.0
Rhinitis3.42.0
Ear Infection3.40
Vaginal Infection3.40
Appendicitis1.70
Furuncle1.70
Pneumonia1.70
Sinusitis Bacterial1.70
Endocarditis02.0
Fungal Skin Infection02.0
Herpes Simplex02.0
Labyrinthitis02.0
Oral Herpes02.0
Respiratory Tract Infection02.0
Sinusitis02.0
SecondaryPercentage of Participants With Malignant Neoplasms Reported During Double-Blind Treatment

All neoplasms were assessed by medical review as to whether or not the event was malignant.

Time frame:
From start of substudy up to 56 days post last dose in the double-blind period or start of the open-label rescue period, whichever occurred first until end of study (study duration was 115 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With Malignant Neoplasms Reported During Double-Blind Treatment
percentage of participantsAbatacept (10 mg/kg)Abatacept (5 mg/kg)
Percentage of Participants With Malignant Neoplasms Reported During Double-Blind Treatment00
SecondaryPercentage of Participants With Prespecified Acute Infusional Adverse Events (AIAEs) During Double-Blind Treatment, by Intensity

AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. Acute Infusional AE= a subset of the peri-infusional AEs with onset during the first hour after the start of the study drug infusion. A total of 105 infusional events were prespecified in the protocol.

Time frame:
From start of substudy up to 56 days post last dose in the double-blind period or start of the open-label rescue period, whichever occurred first until end of study (study duration was 115 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With Prespecified Acute Infusional Adverse Events (AIAEs) During Double-Blind Treatment, by Intensity
percentage of participantsAbatacept (10 mg/kg)Abatacept (5 mg/kg)
Total Participants with AIAEs (mild)02.0
Total Participants with AIAEs (moderate)00
Total Participants with AIAEs (severe)00
Total Participants with AIAEs (very severe)00
Vascular Disorders - Hypertension (mild)02.0
Vascular Disorders - Hypertension (moderate)00
Vascular Disorders - Hypertension (severe)00
Vascular Disorders - Hypertension (very severe)00
Vascular Disorders - Hypertension (unknown)00
SecondaryPercentage of Participants With Prespecified Peri-Infusional Adverse Events (PAIAEs) During Double-Blind Treatment, by Intensity

AE=any new untoward medical occurrence or worsening of a pre-existing medical condition in a subject administered an investigational product and that does not necessarily have a causal relationship with this treatment. Peri-infusional AE=a pre-specified infusional AE occuring during the first 24 hours after the start of study drug infusion.A total of 105 infusional events were prespecified in the protocol. GDASC=General Disorders and Administration Site Conditions, RTMD=Respiratory, Thoracic and Mediastinal Disorders.

Time frame:
From start of substudy up to 56 days post last dose in the double-blind period or start of the open-label rescue period, whichever occurred first until end of study (study duration was 115 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With Prespecified Peri-Infusional Adverse Events (PAIAEs) During Double-Blind Treatment, by Intensity
percentage of participantsAbatacept (10 mg/kg)Abatacept (5 mg/kg)
Total Participants with PIAEs (mild)6.94.0
Total Participants with PIAEs (moderate)1.70
Total Participants with PIAEs (severe)00
Total Participants with PIAEs (very severe)00
Gastrointestinal Disorders, Nausea (mild)1.70
Gastrointestinal Disorders, Nausea (moderate)00
Gastrointestinal Disorders, Nausea (severe)00
Gastrointestinal Disorders, Nausea (very severe)00
Gastrointestinal Disorders, Vomiting (mild)1.70
Gastrointestinal Disorders, Vomiting (moderate)00
Gastrointestinal Disorders, Vomiting (severe)00
Gastrointestinal Disorders, Vomiting (very severe)00
Nervous System Disorders, Dizziness (mild)1.70
Nervous System Disorders, Dizziness (moderate)00
Nervous System Disorders, Dizziness (severe)00
Nervous System Disorders, Dizziness (very severe)00
Nervous System Disorders, Headache (mild)00
Nervous System Disorders, Headache (moderate)1.70
Nervous System Disorders, Headache (severe)00
Nervous System Disorders, Headache (very severe)00
GDASC, Malaise (mild)1.70
GDASC, Malaise (moderate)00
GDASC, Malaise (severe)00
GDASC, Malaise (very severe)00
GDASC, Chest Pain (mild)02.0
GDASC, Chest Pain (moderate)00
GDASC, Chest Pain (severe)00
GDASC, Chest Pain (very severe)00
RTMD, Asthma (mild)1.70
RTMD, Asthma (moderate)00
RTMD, Asthma (severe)00
RTMD, Asthma (very severe)00
RTMD, Cough (mild)1.70
RTMD, Cough (moderate)00
RTMD, Cough (severe)00
RTMD, Cough (very severe)00
Vascular Disorders, Hypertension (mild)02.0
Vascular Disorders, Hypertension (moderate)00
Vascular Disorders, Hypertension (severe)00
Vascular Disorders, Hypertension (very severe)00
SecondaryPercentage of Participants With Pre-specified Autoimmune Disorders (ADs) Reported During Double-Blind Treatment, by Intensity

A total of 127 autoimmune disorders were prespecified in the protocol. MCTD=Musculoskeletal and Connective Tissue Disorders

Time frame:
From start of substudy up to 56 days post last dose in the double-blind period or start of the open-label rescue period, whichever occurred first until end of study (study duration was 115 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With Pre-specified Autoimmune Disorders (ADs) Reported During Double-Blind Treatment, by Intensity
percentage of participantsAbatacept (10 mg/kg)Abatacept (5 mg/kg)
Total Participants with ADs (mild)04.0
Total Participants with ADs (moderate)00
Total Participants with ADs (severe)00
Total Participants with ADs (very severe)00
Eye Disorders - Episcleritis (mild)02.0
Eye Disorders - Episcleritis (moderate)00
Eye Disorders - Episcleritis (severe)00
Eye Disorders - Episcleritis (very severe)00
MCTDs - Sjogren's Syndrome (mild)02.0
MCTDs - Sjogren's Syndrome (moderate)00
MCTDs - Sjogren's Syndrome (severe)00
MCTDs - Sjogren's Syndrome (very severe)00
SecondaryPercentage of Participants With Laboratory Values Meeting the Marked Abnormality Criteria During Double-Blind Treatment

Not evaluated: high hemoglobin,high hematocrit,high erythrocytes,high neutrophils+bands(N+B),low monocytes,low basophils,low eosinophils,low alkaline phosphatase(ALP),low aspartate aminotransferase(AST),low alanine aminotransferase(ALT),low G-Glutamyl transferase(GGT),low total bilirubin,low blood urea nitrogen,low creatinine,high albumin,low uric acid,low urine protein,low urine glucose,low urine blood,low urine leukocyte esterase,low urine white blood cells,low red blood cells.Pre Rx=pretreatment,(\*)Lymphocytes(c/uL):Low\<.750x10\^3,High\>7.50x10\^3.(\*)Eosinophils:\>.750x10\^3 c/uL.

Time frame:
From start of substudy up to 56 days post last dose in the double-blind period or start of the open-label rescue period, whichever occurred first until end of study (study duration was 115 weeks)
Reported as:
Number · percentage of participants
Percentage of Participants With Laboratory Values Meeting the Marked Abnormality Criteria During Double-Blind Treatment
percentage of participantsAbatacept (10 mg/kg)Abatacept (5 mg/kg)
Hemoglobin, Low: >3 g/dL ↓ from pre rx (n=51, 48)00
Hematocrit, Low: <0.75 x pre rx (n=51, 48)00
Erythrocytes, Low: <0.75 x pre rx (n=51, 48)00
ALP, High: >2 x upper limit normal (ULN)(n=52, 47)00
Total Calcium, Low: <0.8 x Lower LN(LLN)(n=52, 47)00
Platelet Count, Low: <0.67 x LLN (n=51, 48)00
Platelet Count, High: >1.5 x ULN (n=51, 48)00
Leukocytes, Low: <0.75 x LLN (n=51, 48)00
N+B (absolute), Low: < 1.00 x 10^3 c/uL (n=55, 49)00
Lymphocytes (absolute), Low (*) (n=55, 49)1.82.0
Lymphocytes (absolute), High (*) (n=55, 49)00
Monocytes (absolute), High: >2000/mm^3 (n=55, 49)00
Basophils (absolute), High: > 400/mm^3 (n=55, 49)00
Eosinophils (absolute), High (*) (n=55, 49)5.52.0
AST, High: >3 x ULN (n=52, 47)00
ALT, High: >3 x ULN (n=52, 47)00
GGT, High: >2 x ULN (n=52, 47)00
Bilirubin Total, High: >1.5 x ULN (n=52, 46)00
Blood Urea Nitrogen, High: >2 x pre rx (n=52, 47)00
Serum Sodium, Low: <0.95 x LLN (n=52, 47)00
Serum Sodium, High: >1.05 x ULN, (n=52, 47)00
Serum Potassium, Low: <0.9 x LLN (n=52, 47)00
Serum Potassium, High: >1.1 x ULN (n=52, 47)02.1
Serum Chloride, Low: <0.9 x LLN (n=52, 47)00
Serum Chloride, High: >1.1 x ULN, (n=52, 47)00
Total Calcium, High: >1.2 x ULN (n=52, 47)00
Inorganic Phosphorus, Low: <0.75 x LLN (n=52, 47)00
Inorganic Phosphorus, High: >1.25 x ULN (n=52, 47)00
Serum Glucose, Low: <65 mg/dL (n=55, 48)5.56.3
Serum Glucose, High: >220 mg/dL (n=55, 48)3.64.2
Total Protein, Low: <0.9 x LLN (n=52, 47)00
Total Protein, High: >1.1 x ULN (n=52, 47)00
Albumin, Low: <0.9 x LLN (n=52, 47)00
Uric Acid, High: >1.5 x ULN (n=52, 47)00
Urine Protein, High: >=2-4 (n=55, 47)1.86.4
Urine Glucose, High: >=2-4 (n=55, 47)5.50
Urine Blood, High: >=2-4 (n=55, 47)12.710.6
Urine Leukocyte Esterase, High: >=2-4 (n=20, 16)15.025.0
Urine White Blood Cells, High: >=2-4 (n=22, 14)45.514.3
Urine Red Blood Cells, High: >=2-4 (n=22, 14)22.728.6
SecondaryClinically Significant Changes in Vital Signs and Physical Findings

Clinical significance was determined by investigator. Parameters include blood pressure, heart rate, respiration rate, and temperature.

Time frame:
From start of substudy up to 56 days post last dose in the double-blind period or start of the open-label rescue period, whichever occurred first until end of study (study duration was 115 weeks)
Reported as:
Number · participants

No measurements were reported for this outcome.

SecondaryParticipants With Positive Antibody Responses to Abatacept (Electrochemiluminescence [ECL] Method) During Double-Blind Treatment

A positive antibody response to Abatacept (measured by the ECL assay) is further classified as a positive response for either Cytotoxic T-Lymphocyte Antigen 4 (CTLA4) and Possibly immunoglobulin (Ig)' or 'Ig and/or Junction Region'

Time frame:
After 12 months of treatment
Reported as:
Number · participants
Participants With Positive Antibody Responses to Abatacept (Electrochemiluminescence [ECL] Method) During Double-Blind Treatment
participantsAbatacept (10 mg/kg)Abatacept (5 mg/kg)
CTLA4 and Possibly IG41
IG and/or Junction Region01

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Abatacept 5mg/kg (ST)—3/50 (6%)17/50 (34%)
Abatacept 10mg/kg (ST)—3/58 (5.2%)18/58 (31%)
Abatacept 10mg/kg (Open-Label)—2/8 (25%)7/8 (87.5%)
Most frequent serious events
Showing 10 of 12
Most frequent serious events
EventAbatacept 5mg/kg (ST)Abatacept 10mg/kg (ST)Abatacept 10mg/kg (Open-Label)
CholelithiasisHepatobiliary disorders0/500/581/8
OsteoarthritisMusculoskeletal and connective tissue disorders1/500/581/8
Rheumatoid ArthritisMusculoskeletal and connective tissue disorders2/500/580/8
LeukopeniaBlood and lymphatic system disorders1/500/580/8
NeutropeniaBlood and lymphatic system disorders1/500/580/8
Cardiopulmonary FailureCardiac disorders1/500/580/8
EndocarditisInfections and infestations1/500/580/8
Diabetes Mellitus Inadequate ControlMetabolism and nutrition disorders1/500/580/8
Renal Failure AcuteRenal and urinary disorders1/500/580/8
AppendicitisInfections and infestations0/501/580/8
Most frequent other events
Showing 10 of 17
Most frequent other events
EventAbatacept 5mg/kg (ST)Abatacept 10mg/kg (ST)Abatacept 10mg/kg (Open-Label)
DiarrhoeaGastrointestinal disorders1/500/582/8
ConjunctivitisEye disorders2/500/581/8
XerophtalmiaEye disorders0/500/581/8
Abdominal DistensionGastrointestinal disorders1/500/581/8
Abdominal Pain UpperGastrointestinal disorders0/500/581/8
Hiatus HerniaGastrointestinal disorders0/500/581/8
VomitingGastrointestinal disorders0/501/581/8
NasopharyngitisInfections and infestations3/503/581/8
Upper Respiratory Tract InfectionInfections and infestations6/503/581/8
OsteoarthritisMusculoskeletal and connective tissue disorders0/501/581/8

Baseline characteristics

Age Continuous
Age Continuous(years)Abatacept (10 mg/kg)Abatacept (5 mg/kg)Total
Mean50.1 ± 11.551.1 ± 13.450.6 ± 12.3
Sex: Female, Male
Sex: Female, Male(Participants)Abatacept (10 mg/kg)Abatacept (5 mg/kg)Total
Female444185
Male14923
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Abatacept (10 mg/kg)Abatacept (5 mg/kg)Total
Unknown202
White494695
Black202
Asian224
Other325
Weight
Weight(kg)Abatacept (10 mg/kg)Abatacept (5 mg/kg)Total
Mean72.9 ± 14.773.8 ± 16.073.4 ± 15.3
Disease Activity Scores Using C-reactive Protein (DAS 28 [CRP])
Disease Activity Scores Using C-reactive Protein (DAS 28 [CRP])(units on a scale)Abatacept (10 mg/kg)Abatacept (5 mg/kg)Total
Mean2.1 ± 0.62.1 ± 0.62.1 ± 0.6
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Westhovens R, Robles M, Ximenes AC, Wollenhaupt J, Durez P, Gomez-Reino J, Grassi W, Haraoui B, Shergy W, Park SH, Genant H, Peterfy C, Becker JC, Murthy B. Maintenance of remission following 2 years of standard treatment then dose reduction with abatacept in patients with early rheumatoid arthritis and poor prognosis. Ann Rheum Dis. 2015 Mar;74(3):564-8. doi: 10.1136/annrheumdis-2014-206149. Epub 2014 Dec 30. PubMed 25550337 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2007, a primary completion of Oct 2009 and a completion of Oct 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2011, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2009
First posted
Oct 5, 2009
Start
Apr 2007
Primary completionActual
Oct 2009
CompletionActual
Oct 2009
Results first posted
Jun 3, 2011
Last update
Jun 21, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 21, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00989235
First posted
Oct 5, 2009
Start date
Apr 2007
Primary completion
Oct 2009
Completion
Oct 2009
Results posted
Jun 3, 2011
Last update
Jun 21, 2011

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abatacept

Start the discussion